Compare ACRV & HDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRV | HDSN |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 252.0M |
| IPO Year | 2022 | 1996 |
| Metric | ACRV | HDSN |
|---|---|---|
| Price | $2.01 | $5.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.67 | $9.00 |
| AVG Volume (30 Days) | 255.5K | ★ 439.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $237,118,000.00 |
| Revenue This Year | N/A | $2.51 |
| Revenue Next Year | $568.17 | $2.38 |
| P/E Ratio | ★ N/A | $42.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $4.64 |
| 52 Week High | $3.56 | $10.06 |
| Indicator | ACRV | HDSN |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 39.93 |
| Support Level | $1.38 | $5.10 |
| Resistance Level | $2.02 | $6.47 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 63.21 | 17.50 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Hudson Technologies Inc is a refrigerant services company providing solutions to recurring challenges within the refrigeration industry. The company delivers environmentally sustainable offerings, covering the sale of refrigerant gases, recovery, reclamation, and reuse, as well as improving equipment performance through energy efficiency services, emergency air conditioning and refrigeration system repairs, refrigerant disposal, and carbon credit trading. It operates through one reportable segment. Its products and services are used in commercial air conditioning, industrial processing, and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services (mainly reclamation of refrigerants), and RefrigerantSide services performed at customer sites.